Invesco Mutual FundEquity Schemes - Small Cap Fund8 years
The scheme seeks to generate capital appreciation by investing predominantly in stocks of Smallcap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 59% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Prefer peers if · Prefer Axis Small Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
8.0 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.64% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -37.7%. Ask whether you can hold through a similar fall.
Vs category
Pass
59% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Aditya Khemani · 3.0 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 36.3% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 38%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
20 Feb 2020 – 24 Nov 2020
Trough 24 Mar 2020 · recovered in 245 days
-37.7%
16 Dec 2024 – 7 May 2026
Trough 3 Mar 2025 · recovered in 430 days
-23.4%
17 Jan 2022 – 8 Dec 2022
Trough 20 Jun 2022 · recovered in 171 days
-22.2%
28 May 2019 – 30 Dec 2019
Trough 22 Aug 2019 · recovered in 130 days
-14.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
100
Vs category
84
Consistency
62
Risk-adjusted
71
Drawdown
6
Mean
65
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 75 holdings · top 10 are 36.3%.
Sai Life Sciences Ltd.
Healthcare
5.1%
Repo
Unspecified
4.5%
Zomato Ltd
Technology
4.4%
Aditya Infotech Ltd.
Technology
4.0%
Amber Enterprises India Ltd
Consumer Discretionary
3.7%
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Axis Mutual Fund
Caveat: Higher TER · Lower trailing returns
Canara Robeco Mutual Fund
Caveat: Higher TER · Lower trailing returns
Mahindra Manulife Mutual Fund
Caveat: Higher TER · Lower trailing returns
Mirae Asset Mutual Fund
Caveat: Higher TER · Lower trailing returns
HSBC Mutual Fund
Caveat: Lower trailing returns
Invesco Mutual FundEquity Schemes - Small Cap Fund8 years
The scheme seeks to generate capital appreciation by investing predominantly in stocks of Smallcap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 59% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Prefer peers if · Prefer Axis Small Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
8.0 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.64% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -37.7%. Ask whether you can hold through a similar fall.
Vs category
Pass
59% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Aditya Khemani · 3.0 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 36.3% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 38%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
29 Oct 2026 · +6.9% over 1Y
51.52
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
29 Oct 2026
-6.1%
20 Feb 2020 – 24 Nov 2020
Trough 24 Mar 2020 · recovered in 245 days
-37.7%
16 Dec 2024 – 7 May 2026
Trough 3 Mar 2025 · recovered in 430 days
-23.4%
17 Jan 2022 – 8 Dec 2022
Trough 20 Jun 2022 · recovered in 171 days
-22.2%
28 May 2019 – 30 Dec 2019
Trough 22 Aug 2019 · recovered in 130 days
-14.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
100
Vs category
84
Consistency
62
Risk-adjusted
71
Drawdown
6
Mean
65
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 75 holdings · top 10 are 36.3%.
Sai Life Sciences Ltd.
Healthcare
5.1%
Repo
Unspecified
4.5%
Zomato Ltd
Technology
4.4%
Aditya Infotech Ltd.
Technology
4.0%
Amber Enterprises India Ltd
Consumer Discretionary
3.7%